Clinical Trials - November 9, 2021
IGM Biosciences initiates study with Medivir’s birinapant
Medivir has announced that IGM Biosciences has initiated its clinical study in solid cancers with birinapant (a k a IGM-9427) in combination with IGM’s DR5 agonist antibody IGM-8444. The combination of IGM-8444 and birinapant has previously shown to enhance anti-tumor activity preclinically, states Medivir. The purpose of this first clinical trial with the combination will […]
In a new job - November 1, 2021
Medivir appoints new Chief Executive Officer
The Board of Directors of Medivir has appointed Jens Lindberg as CEO of the company. ”I am delighted about our recruitment of Jens Lindberg as CEO. He has the ideal personality and experience for this job. Jens brings relevant skills both when it comes to building successful organizations and in developing and commercializing medicines for […]
Pharma Business - September 8, 2021
Medivir receives regulatory approval from MHRA
The company has received regulatory approval from the British Medicines & Healthcare products Regulatory Agency (MHRA) for its upcoming phase 1/2a combination study with the company’s leading candidate drug MIV-818 against liver cancer. In the study, MIV-818 will be administered in two combinations, either with lenvatinib, a tyrosine kinase inhibitor or pembrolizumab, an anti-PD-1 check-point […]
Pharma Business - August 17, 2021
Medivir renegotiates multi-party agreement
Medivir together with the originators of remetinostat, and TetraLogic Pharmaceuticals Corporation and the Leukemia & Lymphoma Society (“the stakeholders”) have restructured and streamlined the financial obligations for remetinostat. The purpose of the new agreement is to create improved business development opportunities, states the company. Remetinostat Remetinostat is a topical histone deacetylase (HDAC) inhibitor, for the […]
In a new job - August 1, 2021
Medivir appoints Vice President Clinical Development
Medivir has appointed Malene Jensen as Vice President Clinical Development. She will assume her role as VP Clinical Development at the latest October 1, 2021. Jensen will also join the company’s executive team. Malene Jensen Malene Jensen has held various leadership positions within Clinical Development in the pharmaceutical industry for the past 15 years, including […]
In a new job - March 24, 2021
The CEO of Medivir leaves the company
Medivir has announced that Yilmaz Mahshid leaves the position as CEO of Medivir. The nomination committee proposes that he is elected as Board Member of the company and that Uli Hacksell is elected new Chairman of the Board. Yilmaz Mahshid has tendered his resignation for personal reasons. Yilmaz Mahshid will remain as CEO until the […]
